{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:08:38Z","timestamp":1784804918764,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.psychres.2019.112660","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T12:20:17Z","timestamp":1572265217000},"page":"112660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Benzodiazepine abuse, misuse, dependence, and withdrawal among schizophrenic patients: A review of the literature"],"prefix":"10.1016","volume":"284","author":[{"given":"Javier I.","family":"de la Iglesia-Larrad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Barral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea M.","family":"Casado-Espada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"de Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Maci\u00e1-Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Vicente Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Roncero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2019.112660_bib0001","article-title":"Diagnostic and statistical manual of mental disorders (5th edition)","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0002","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011481.pub2","article-title":"Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users","author":"Baandrup","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.psychres.2019.112660_bib0003","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.psychres.2016.04.031","article-title":"Objective and subjective sleep quality: melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use","volume":"240","author":"Baandrup","year":"2016","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2019.112660_bib0004","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00005053-198907000-00003","article-title":"Alcohol and substance abuse among schizophrenic patients presenting to an emergency psychiatric service","volume":"177","author":"Barbee","year":"1989","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.psychres.2019.112660_bib0005","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/schbul\/21.2.313","article-title":"Assessment of alcohol and other drug disorders in the seriously mentally III","volume":"21","author":"Barry","year":"1995","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2019.112660_bib0006","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.encep.2010.08.009","article-title":"Pharmacological management of anxiety in patients suffering from schizophrenia","volume":"37","author":"Bayl\u00e9","year":"2011","journal-title":"Encephale"},{"key":"10.1016\/j.psychres.2019.112660_bib0007","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/archpsyc.63.4.426","article-title":"A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness","volume":"63","author":"Bellack","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0008","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/00952999109001598","article-title":"Substance abuse in an inpatient psychiatric sample","volume":"17","author":"Brady","year":"1991","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.psychres.2019.112660_bib0009","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1176\/appi.ps.54.10.1395","article-title":"Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders","volume":"54","author":"Brunette","year":"2003","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.psychres.2019.112660_bib0010","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1176\/ps.2006.57.8.1094","article-title":"Baseline use of concomitant psychotropic medications to treat schizophrenia in the catie trial","volume":"57","author":"Chakos","year":"2006","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.psychres.2019.112660_bib0011","first-page":"7","article-title":"Issues in the clinical use of benzodiazepines potency withdrawal and rebound","volume":"65","author":"Chouinard","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0012","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4088\/JCP.v65n0202","article-title":"Benzodiazepine prescription practices and substance abuse in persons with severe mental illness","volume":"65","author":"Clark","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0013","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1465-3362.2009.00101.x","article-title":"Benzodiazepine use among heroin users: baseline use, current use and clinical outcome","volume":"29","author":"Darke","year":"2010","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.psychres.2019.112660_bib0014","first-page":"224","article-title":"Drug abuse in schizophrenic patients: clinical correlates and reasons for use","author":"Dixon","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1176\/ajp.149.3.421b","article-title":"Response of schizophrenic patients to benzodiazepines","volume":"149","author":"Dreher","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0016","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S0013-7006(06)76280-7","article-title":"Benzodiaz\u00e9pines et schizophr\u00e9nie, revue de la litt\u00e9rature","volume":"32","author":"Gaillard","year":"2006","journal-title":"LEnc\u00e9phale"},{"key":"10.1016\/j.psychres.2019.112660_bib0017","article-title":"Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis","author":"Gillies","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.psychres.2019.112660_bib0018","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/ADM.0000000000000024","article-title":"Observational study on medications prescribed to dual-diagnosis outpatients","volume":"8","author":"Grau-\u0139opez","year":"2014","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.psychres.2019.112660_bib0019","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF03033480","article-title":"Pharmacotherapy for schizophrenia and co-occurring substance use disorders","volume":"11","author":"Green","year":"2007","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.psychres.2019.112660_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/S0033-3182(86)72612-1","article-title":"Benzodiazepines in schizophrenia","author":"Greenstein","year":"1986","journal-title":"Psychosomatics"},{"key":"10.1016\/j.psychres.2019.112660_bib0021","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/0269881106072386","article-title":"Benzodiazepines - A necessary evil? A survey of prescribing at a specialist UK psychiatric hospital","volume":"21","author":"Haw","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2019.112660_bib0022","first-page":"751","article-title":"Prescription drug misuse: a growing national problem","volume":"17","author":"Hertz","year":"2006","journal-title":"Adolesc. Med. Clin."},{"key":"10.1016\/j.psychres.2019.112660_bib0023","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/10673220902724599","article-title":"Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence","volume":"17","author":"Horsfall","year":"2009","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0024","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.psychres.2010.10.027","article-title":"Use of antipsychotics - An analysis of lifetime treatment in 66 patients with psychoses","volume":"187","author":"J\u00f6nsson","year":"2011","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2019.112660_bib0025","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1742-1241.2009.02191.x","article-title":"Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients","volume":"63","author":"Karagianis","year":"2009","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.psychres.2019.112660_bib0026","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/comp.2002.35910","article-title":"Comorbidity of substance abuse and other psychiatric disorders in acute general psychiatric admissions: a study from Lebanon","volume":"43","author":"Karam","year":"2002","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0027","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003495-200262050-00003","article-title":"Substance misuse in patients with schizophrenia: epidemiology and management","volume":"62","author":"Kavanagh","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.psychres.2019.112660_bib0028","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.addbeh.2011.09.010","article-title":"Treatment of substance abusing patients with comorbid psychiatric disorders","volume":"37","author":"Kelly","year":"2012","journal-title":"Addict. Behav."},{"key":"10.1016\/j.psychres.2019.112660_bib0029","article-title":"Benzodiazepine dependence danger","volume":"6","author":"Khong","year":"2016","journal-title":"Nurs. Stand."},{"key":"10.1016\/j.psychres.2019.112660_bib0030","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.pnpbp.2011.11.008","article-title":"Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic","volume":"36","author":"Kitajima","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0031","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","article-title":"Benzodiazepines revisited-will we ever learn?","volume":"106","author":"Lader","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.psychres.2019.112660_bib0032","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3109\/10398562.2011.579971","article-title":"Alcohol and substance use by patients with psychosis presenting to an emergency department: changing patterns","volume":"19","author":"Latt","year":"2011","journal-title":"Australas. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0033","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/00952998908993409","article-title":"Drug abuse in schizophrenia and bipolar disorder","volume":"15","author":"Miller","year":"1989","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.psychres.2019.112660_bib0034","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/02791072.1997.10400198","article-title":"The integration of pharmacological therapy for comorbid psychiatric and addictive disorders","volume":"29","author":"Miller","year":"1997","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.psychres.2019.112660_bib0035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/BF03033068","article-title":"Use of potentially abusive psychotropic substances in psychiatric inpatients","volume":"247","author":"Modestin","year":"1997","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2019.112660_bib0036","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archgenpsychiatry.2009.175","article-title":"National trends in psychotropic medication polypharmacy in office-based psychiatry","volume":"67","author":"Mojtabai","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0037","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1037\/0022-006X.60.6.845","article-title":"Comorbidity of schizophrenia and substance abuse: implications for treatment","volume":"60","author":"Mueser","year":"1992","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.psychres.2019.112660_bib0038","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0447.1992.tb01441.x","article-title":"Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder","volume":"85","author":"Mueser","year":"1992","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psychres.2019.112660_bib0039","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/schbul\/16.1.31","article-title":"Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Special issue:\u202f: prevalence of substance abuse in schizophrenia: demographic and clinical correlates","volume":"16","author":"Mueser","year":"1990","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2019.112660_bib0040","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.biopsych.2004.10.002","article-title":"Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action","volume":"56","author":"O\u2019Brien","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0041","first-page":"122","article-title":"Innovative uses of benzodiazepines in psychiatry","volume":"38","author":"Pollack","year":"1993","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0042","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.schres.2017.09.026","article-title":"Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders","volume":"195","author":"R\u00f8mer Thomsen","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2019.112660_bib0043","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/ADT.0b013e318227ecdc","article-title":"Protocols of dual diagnosis intervention in schizophrenia","volume":"10","author":"Roncero","year":"2011","journal-title":"Addict. Disord. Treat."},{"key":"10.1016\/j.psychres.2019.112660_bib0044","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1192\/bjp.154.6.839","article-title":"Prevalence of benzodiazepine abuse and dependence in-psychiatric in-patients with different nosology","volume":"154","author":"Schmidt","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/schbul\/16.1.111","article-title":"Pharmacological treatment of substance-abusing schizophrenic patients","volume":"16","author":"Siris","year":"1990","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2019.112660_bib0046","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/0010-440X(88)90074-0","article-title":"Histories of substance abuse in patients with postpsychotic depressions","volume":"29","author":"Siris","year":"1988","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0047","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF02190250","article-title":"Prevalence of alcohol and drug abuse in schizophrenic inpatients","volume":"242","author":"Soyka","year":"1993","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2019.112660_bib0048","first-page":"1","article-title":"Medication, hospitalizations and mortality in 5 years after first-episode psychosis in a Swedish nation-wide cohort","author":"Str\u00e5lin","year":"2018","journal-title":"Early Interv. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ADT.0b013e31826e7b6a","article-title":"Rethinking dual disorders\/pathology","volume":"12","author":"Szerman","year":"2013","journal-title":"Addict. Disord. their Treat"},{"key":"10.1016\/j.psychres.2019.112660_bib0050","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/appi.ajp.2015.15050618","article-title":"Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study","volume":"173","author":"Tiihonen","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0051","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/ebmental-2012-100866","article-title":"Use of benzodiazepines in adults with schizophrenia is associated with increased mortality","volume":"15","author":"Tiihonen","year":"2012","journal-title":"Evid. Based. Ment. Health"},{"key":"10.1016\/j.psychres.2019.112660_bib0052","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archgenpsychiatry.2011.1532","article-title":"Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia","volume":"69","author":"Tiihonena","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0053","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1185\/030079907X233214","article-title":"How expensive is antipsychotic polypharmacy? Experience from five US state medicaid programs","volume":"23","author":"Valuck","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.psychres.2019.112660_bib0054","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/hup.1209","article-title":"Concomitant medication of psychoses in a lifetime perspective","volume":"26","author":"Vares","year":"2011","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2019.112660_bib0055","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1176\/appi.ajp.158.8.1181","article-title":"Drug abuse and mental illness: progress in understanding comorbidity","volume":"158","author":"Volkow","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2019.112660_bib0056","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006391","article-title":"Benzodiazepines for schizophrenia","author":"Volz","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.psychres.2019.112660_bib0057","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1176\/appi.ps.56.3.283","article-title":"Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice","volume":"56","author":"West","year":"2005","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.psychres.2019.112660_bib0058","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0924-977X(99)00053-X","article-title":"The use and development of anxiolytics in Japan","volume":"9","author":"Yamawaki","year":"1999","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2019.112660_bib0059","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/YCO.0b013e3283366427","article-title":"Polypharmacy in schizophrenia","volume":"23","author":"Zink","year":"2010","journal-title":"Curr. Opin. Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178119316269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178119316269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:43:02Z","timestamp":1759038182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178119316269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":59,"alternative-id":["S0165178119316269"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2019.112660","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benzodiazepine abuse, misuse, dependence, and withdrawal among schizophrenic patients: A review of the literature","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2019.112660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112660"}}